PRESS RELEASES

ATMI, Inc. - ATMI Announces Technology Investments With Medinstill

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



ATMI Announces Technology Investments With Medinstill

Partnership to Deliver Sterile Connector and Fill Technology

Provides Quicker Set-Up, Greater Flexibility, Lower Costs and Faster Access to Medicines

DANBURY, Conn., Sept. 17, 2013 (GLOBE NEWSWIRE) -- ATMI, Inc. (Nasdaq:ATMI), a global technology company and leader in single-use bioprocess solutions, announced today it has invested in sterile connector and sterile fill technology developed by Medical Instill Technologies (Medinstill), a company dedicated to developing solutions for the transfer and packaging of high purity fluids at unmatched safety levels.

The investments focus on the INTACT™ family of products developed by Medinstill. These innovative technologies will be deployed in sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilization solutions that address current critical issues in the pharmaceutical, biotech, and healthcare industries.

"ATMI has a strong history of internal innovation as well as collaboration with other innovators," said Chief Executive Office of ATMI, Doug Neugold. "Collaboration with Medinstill is another great example of this strategy. Through this investment, we will develop a suite of products that address critical issues from our customers' perspective as they continue to adopt single-use technology and other new inventions. "Our customers are looking for ways to reduce cost, minimize time to market and increase manufacturing flexibility. The INTACT solutions that we are developing with Medinstill enable efficiencies that will help us help them realize their objectives."

"We are happy to partner with a company of ATMI's stature," added Daniel Py, MD, Sc.D., Chairman of Medinstill. "With its global reach and history of technical innovation in biopharmaceutical manufacturing, I believe ATMI can be instrumental in allowing us to bring products with the highest safety levels to those in need. The INTACT technology provides a means to rapidly reduce drug shortages while overcoming the difficulties associated with installing and running aseptic lines in emerging markets, such as access to specially trained personnel, all at a fraction of the cost of traditional aseptic filling lines. The synergy between our INTACT Closed Transfer Systems and disposable technologies from ATMI allows us together to quickly install turn-key fill finish lines, bringing many benefits to a large number of manufacturers. We look forward to a long and successful relationship with ATMI."

INTACT Filler technology allows for sterile fill of multiple products into a broad range of containers and dosing devices in conditions significantly less stringent and less expensive than clean rooms, providing an avenue for meeting demand in domestic and international locations. ATMI and Medinstill have formed a joint venture to market and manufacture this technology for the biopharmaceutical industry. The technology is scalable from small lots in benchtop systems to industrial scales that enable the global biopharmaceutical and vaccine markets.

INTACT Connector technology will allow for sterile re-use of disposable connectors. ATMI has exclusively licensed this technology for the biopharmaceutical industry and will directly commercialize the connector products once development activity is completed. The INTACT connector technology will be the only multiple-use sterile connector, which guarantees no contact between the liquid path and the external environment and ensures no ingress of air, bacteria, yeasts or mold. The INTACT Sterile connector technology is a major breakthrough for situations requiring transfers of fluids under sterile conditions without a controlled environment for the pharmaceutical and bioprocessing industries.

About ATMI

ATMI, Inc. provides specialty semiconductor materials, and safe, high-purity materials handling and delivery technologies designed to increase process efficiencies for the global semiconductor, flat panel, and life sciences industries. For more information, please visit http://www.atmi.com.

About ATMI LifeSciences

ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world. For more information, please visit www.atmi-lifesciences.com.

About Medinstill

Medical-Instill Technologies is a company dedicated to the invention, development and commercialization of technologies for the contamination free manufacturing and delivery of pharmaceutical, cosmetic and nutrition products. Medinstill holds over 100 patents for the contamination free filling and multiple dose delivery for non-preserved products. In addition, Medinstill's devices are conceived for enhancing drug efficacy and reducing side effects through accurate, consumer friendly, metered dose delivery systems for topical applications on skin and mucous membranes. Medinstill continues to pursue partnerships and licenses for the commercialization of their filling technology and delivery devices in specific fields.

ATMI and the ATMI logo are trademarks, or registered trademarks, of Advanced Technology Materials, Inc., in the United States, other countries or both.

MEDINSTILL and INTACT are trademarks of Medical Instill Technologies, Inc. and are Reg. U.S. Pat. & Tm. Off. and in other countries.

Forward Looking Statements

Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI's anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations only and are subject to certain risks, uncertainties, and assumptions, including, but not limited to, changes in semiconductor and life sciences industry growth (including, without limitation, wafer starts) or ATMI's markets; competition, problems, or delays developing, commercializing, and delivering new products; customer-driven pricing pressure; potential loss of key customers; problems or delays in integrating acquired operations and businesses; uncertainty in the credit and financial markets; ability to protect ATMI's proprietary technology; and other factors described in ATMI's Form 10-K for the year ended December 31, 2012 and other subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties may cause actual results to differ materially from those expressed in our forward-looking statements. ATMI undertakes no obligation to update any forward-looking statements.

CONTACT: ATMI Contact:

         Troy Dewar

         Director of Investor Relations and Corporate Communications

         203.207.9349

         tdewar@atmi.com



         Media Contact:

         Beth Willers

         Impress Labs

         415.846.9891

         beth@impresslabs.com

company logo

Source: ATMI, Inc.

News Provided by Acquire Media

Close window | Back to top

Stock Information
NASDAQ:ATMI
$33.99   + 0.02
Apr 17, 2014
4:00 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.

Transfer Agent
Continental Stock Transfer & Trust Company
17 Battery Place – 8th Floor
New York, NY 10004
Attn. Transfer Department
1-800-509-5586 or
212-509-4000
cstmail@continentalstock.com